TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28854066
Drug: Dacarbazine (850,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dacarbazine (850, 1,000, or 1,200 mg/m2 intravenously on day 1 every 21 days)
Study: 16543297
Drug: Training and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training and support intervention delivered to nursing home staff over 10 months, focusing on alternatives to drugs for the management of agitated behaviour in dementia
Study: 8250308
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine added to general anesthesia
Study: 30322751
Drug: Ringer's acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's acetate (1000 mL bolus)
Study: 21402860
Drug: 200‐mg rifamycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200‐mg rifamycin SV MMX modified‐release tablets
Study: 18496232
Drug: Prednisolone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (1 mg/kg/d)
Study: 18496232
Drug: Budesonide (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide (9 mg/d)
Study: 12714403
Drug: Viscocanalostomy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viscocanalostomy with reticulated hyaluronic acid implant (VSRHAI)
Study: 21801403
Drug: AMG 108
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMG 108 (300 mg SC)
Study: 12828691
Drug: Four double-pass
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four double-pass treatments at 2-week intervals
Study: 8497683
Drug: ONO‐1078 (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO‐1078 (225 mg twice a day)
Study: 21459680
Drug: Celecoxib 50
Normalized name: celecoxib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 50 mg bid
Study: 22859357
Drug: Celecoxib 800/400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 800/400 mg
Study: 8441139
Drug: Indomethacin 50
Normalized name: indomethacin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin 50 mg tid
Study: 15877867
Drug: Carrot juice
Normalized name: carrot juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrot juice (330 ml/d, 27.1 mg beta-carotene, 13.1 mg alpha-carotene) for 2 weeks
Study: 12929855
Drug: Deltamethrin-treated mosquito
Normalized name: mosquito allergenic extract
DrugBank: Aedes taeniorhynchus (DB10691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltamethrin-treated mosquito nets, mosquito repellent cream, and weekly chemoprophylaxis with 300 mg chloroquine
Study: 11405384
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg rofecoxib
Study: 15309591
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg rofecoxib
Study: 1486963
Drug: Piretanide (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piretanide (24 mg)
Study: 22216503
Drug: Frusemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (40 mg)
Study: 24667502
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lectures and dissection-based laparoscopic training (Group III)
Study: 22193388
Drug: Epoetin-β to
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epoetin-β to normalize hemoglobin values (13.0-15.0 g/dl)
Study: 22193388
Drug: Partial correction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial correction of anemia (10.5-11.5 g/dl)
Study: 18843939
Drug: Placebo or
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo or typical/atypical antipsychotics
Study: 2658526
Drug: Flosequinan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flosequinan (100 mg)
Study: 27058964
Drug: Stabilization splint
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stabilization splint therapy
Study: 28013329
Drug: Cisatracurium besylate
Normalized name: Cisatracurium Besylate
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisatracurium besylate (NMBA) continuous infusion for 48 hours in moderate ARDS patients
Study: 23018283
Drug: Clozapine suspension
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clozapine suspension and Clozaril(®) tablets
Study: 9928544
Drug: Estrogen/hormone replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen/hormone replacement therapy (ERT/HRT)
Study: 8585289
Drug: Monovalent liposome‐adjuvanted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monovalent liposome‐adjuvanted vaccine
Study: 8585289
Drug: Licensed trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licensed trivalent subvirion vaccine (reimmunization after 18 weeks)
Study: 2816237
Drug: Thiopentone 6
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 6 mg/kg as a rapid intravenous bolus during CPB
Study: 28969611
Drug: Web-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based intervention consisting of 10 modules tailored to treatment type, relationship status, and sexual orientation.
Study: 18352915
Drug: Pamphlets +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamphlets + Lecture (P + L)
Study: 17075906
Drug: Pharmacotherapy combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacotherapy combined with cognitive behavioral therapy (CBT)
Study: 17075906
Drug: Pharmacological agents
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological agents
Study: 24360599
Drug: Fluoxetine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine treatment
Study: 11441210
Drug: Conventional aphasia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional aphasia therapy
Study: 1983347
Drug: sufotidine 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: sufotidine 600 mg nocte
Study: 28715907
Drug: Immediate prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate prolonged exposure treatment
Study: 7799116
Drug: Ibuprofen and
Normalized name: Ibuprofen and Famotidine Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and methylprednisolone
Study: 1971708
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg of propafenone every eight hours for five days
Study: 1971708
Drug: 225 mg
Normalized name: tyrosine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg of propafenone every eight hours for five days
Study: 1971708
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg of propafenone every eight hours for five days
Study: 29200757
Drug: Topical amorolfine
Normalized name: amorolfine Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical amorolfine lacquer monotherapy
Study: 11176912
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg once daily for 7 days
Study: 9589380
Drug: n-3 PUFA
Normalized name: 22:6(n-3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 PUFA (6 g, reduced to 3 g from day +30)
Study: 8113551
Drug: Warfarin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin plus antiplatelet therapy
Study: 26345129
Drug: 1% flutamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% flutamide cream
Study: 15637977
Drug: Re-dosing regimen
Normalized name: Re-Covr
Approvals — FDA: no, EMA: no, PMDA: no
Description: Re-dosing regimen (2 doses at the start of brushing with 1 additional in-mouth dose during the last 30 seconds of brushing [2+1])
Study: 15637977
Drug: Conventional regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional regimen (2 doses at the start of brushing only [2+0])
Study: 26799502
Drug: Maternal stimulant
Normalized name: Staphylococcus simulans
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal stimulant medication (MSM)
Study: 23337174
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg glucagon
Study: 10021958
Drug: 1 ml
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml saline
Study: 12444816
Drug: Hydroxyzine (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine (50 mg/day)
Study: 27473633
Drug: Morning light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning light treatment (1 hour for 6 days)
Study: 27473633
Drug: Evening light
Normalized name: Evenity
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Evening light treatment (1 hour for 6 days)
Study: 27473633
Drug: Both morning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both morning and evening light treatments
Study: 26090395
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids and Meriva (curcumin) at 2 g per day for 12 weeks
Study: 26090395
Drug: Topical steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical steroids alone for 12 weeks
Study: 19540105
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + Vitamin E (100 mg t.i.d.)
Study: 16431252
Drug: Methylprednisolone alternated
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone alternated with a cytotoxic drug every other month for 6 months (group A)
Study: 16431252
Drug: Synthetic adrenocorticotropic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic adrenocorticotropic hormone administered twice a week for 1 year (group B)
Study: 11694408
Drug: rHuEpo and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: rHuEpo and G-CSF
Study: 20304348
Drug: parecoxib 20
Normalized name: parecoxib 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: parecoxib 20 mg
Study: 17982319
Drug: parecoxib 40
Normalized name: Parécoxib
DrugBank: Parecoxib (DB08439)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: parecoxib 40 mg
Study: 16336326
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (MVAC/MVEC)
Study: 11600586
Drug: Ibuprofen (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (1200 mg/d)
Study: 3236318
Drug: Amiloride 10
Normalized name: amiloride 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride 10 mg once daily
Study: 2550642
Drug: Lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril 20 mg once daily
Study: 27811556
Drug: Sertraline (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (mean dosage 123.8 mg/d, range 50-200 mg/d)
Study: 24533896
Drug: Fluoxetine (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (normal pH subgroup)
Study: 24533896
Drug: Fluoxetine (abnormal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (abnormal pH subgroup)
Study: 19155748
Drug: Melatonin (8.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin (8.5 mg immediate release and 1.5 mg sustained release)
Study: 17484223
Drug: Measles Vaccine
Normalized name: Measles vaccine
DrugBank: Measles virus vaccine live attenuated (DB10315)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Measles Vaccine (MV) as the most recent vaccine
Study: 963493
Drug: Nimorazole (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimorazole (300 mg twice daily for 7 days)
Study: 963493
Drug: Metronidazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole (200 mg three times a day for 7 days)
Study: 25491597
Drug: Eplerenone 100
Normalized name: eplerenone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 100 mg
Study: 12094341
Drug: Gemcitabine/cisplatin combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine/cisplatin combination
Study: 12975670
Drug: M-VAC combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-VAC combination chemotherapy
Study: 14684762
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of flaxseed
Study: 14684762
Drug: 28 g
Normalized name: SM Syringe 28 g, 0.5cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 g of wheat bran
Study: 14684762
Drug: 10 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 g of flaxseed plus 28 g of wheat bran
Study: 2859739
Drug: Propranolol 80
Normalized name: propranolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 80 mg (control)
Study: 30130991
Drug: Group C:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C: B + physical and psychological approaches to LBP treatment
Study: 22017169
Drug: Osteopontin levels
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osteopontin levels in women (mean ± SD: 51.7 ± 16.0 μg/mL)
Study: 10757134
Drug: 0.62 g/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.62 g/kg of alcohol
Study: 9282804
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of acetazolamide (Diamox) intravenous injection
Study: 29226816
Drug: Subcutaneous furosemide
Normalized name: Furosemide
DrugBank: Furosemide (DB00695)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous furosemide (SC)
Study: 24923685
Drug: 91-day extended
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 91-day extended regimen combined oral contraceptive (150 μg levonorgestrel [LNG]/30 μg ethinylestradiol [EE] for 84 days, followed by 10 μg EE for seven days)
Study: 24923685
Drug: Traditional 21/7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional 21/7 regimen (21 days 150 μg LNG/30 μg EE)
Study: 21702861
Drug: Routine prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine prevention (six-hourly repositioning using 90° lateral rotation) (control group)
Study: 12568305
Drug: Granisetron alone
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron alone (G group)
Study: 11594407
Drug: Cerivastatin 0.8
Normalized name: cerivastatin 0.8 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.8 mg
Study: 11594407
Drug: Cerivastatin 0.4
Normalized name: cerivastatin 0.4 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerivastatin 0.4 mg
Study: 9352727
Drug: Intensive neurodevelopmental
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive neurodevelopmental therapy (NDT) plus casting
Study: 24986270
Drug: Cure‐allergic‐rhinitis Syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cure‐allergic‐rhinitis Syrup (CS)
Study: 7635028
Drug: Oral formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulations of mesalazine
Study: 2658438
Drug: Insulin coma
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin coma (IC) after pharmacotherapy with mageptil, chlorpromazine, melipramine
Study: 2658438
Drug: Insulin coma
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin coma (IC) after pharmacotherapy with haloperidol, triphtazin, amitriptyline
Study: 2658438
Drug: Insulin coma
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin coma (IC) after benzodiazepines
Study: 2658438
Drug: Insulin coma
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin coma (IC) therapy
Study: 2658438
Drug: Insulin coma
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin coma (IC) in drug-free patients
Study: 28622178
Drug: Lumbar Epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar Epidural (LE) with 0.125% bupivacaine and 50 μg fentanyl
Study: 20418251
Drug: General practitioner
Approvals — FDA: no, EMA: no, PMDA: no
Description: General practitioner treatment as usual (n=100)
Study: 27937053
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg single oral dose
Study: 15613405
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose testosterone administration
Study: 7867678
Drug: mizolastine 20
Normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mizolastine 20 mg
Study: 7867678
Drug: mizolastine 5
Normalized name: mizolastine
DrugBank: Mizolastine (DB12523)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mizolastine 5 mg
Study: 7867678
Drug: clemastine 2
Normalized name: clemastine 2 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: clemastine 2 mg
Study: 2572902
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg pamidronate as a single intravenous infusion
Study: 2572902
Drug: Etidronate as
Normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etidronate as three infusions of 7.5 mg/kg per day for three consecutive days
Study: 792994
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg terbutaline inhaled via IPPB
Study: 792994
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg terbutaline inhaled via IPPB
Study: 31823444
Drug: Risperidone (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (2, 4 or 6 mg/day)
Study: 3165190
Drug: Chemomechanical preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemomechanical preparation
Study: 15347339
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream (three times weekly)
Study: 15347339
Drug: Imiquimod 5%
Normalized name: Imiquimod 5% Topical cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imiquimod 5% cream (five times weekly)
Study: 9568413
Drug: Neoral at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoral at 2.5 mg/kg/day or equivalent to pre-conversion SIM dosage
Study: 403149
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of tritium-labeled ergot alkaloids
Study: 27583439
Drug: Lipid solutions
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid solutions delivered separately (Group 1)
Study: 27583439
Drug: Lipid solutions
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid solutions in mixture with TPN solutions (Group 2)
Study: 15520986
Drug: Inactivated influenza
Normalized name: influenza, inactivated, whole virus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated influenza vaccine (intramuscular administration)
Study: 8418313
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy followed by standard therapy with surgery and/or radiation
Study: 3080575
Drug: Ibuprofen (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (25 mg/kg/day)
Study: 3080575
Drug: Indomethacin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (2 mg/kg/day)
Study: 2682120
Drug: Aminophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminophylline (6 mg/kg over 15 minutes)
Study: 30847474
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg maintenance dose starting at Week 6
Study: 28100440
Drug: Web Behavior
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Web Behavior Change Program for Activity (Web‐BCPA) in combination with multimodal rehabilitation (MMR)
Study: 26286532
Drug: Post-treatment pain
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment pain alone
Study: 26286532
Drug: Pre-treatment predictor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment predictor models
Study: 14634864
Drug: Cyclophosphamide, 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide, 90 mg/m(2)/day for 42 days
Study: 9631379
Drug: NSAID (non-steroidal
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID (non-steroidal anti-inflammatory drugs)
Study: 2591089
Drug: Oil-in-water emulsion
Normalized name: mineral oil
DrugBank: Mineral oil (DB11057)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oil-in-water emulsion applied twice daily for 7 days
Study: 26066384
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg intravenous
Study: 16765179
Drug: alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfuzosin 10 mg daily + tadalafil 20 mg
Study: 16765179
Drug: alfuzosin 10
Normalized name: Alfuzosin 10mg Oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfuzosin 10 mg daily + placebo
Study: 11903327
Drug: Different classes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Different classes of drug for blood pressure lowering
Study: 17314584
Drug: Diclofenac 75
Normalized name: CAPSAICIN 0.025%/DICLOFENAC 75MG KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 75 mg b.i.d.
Study: 8866631
Drug: Urapidil (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urapidil (60 mg)
Study: 31044510
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant placement combined with maxillary sinus floor elevation utilizing the transalveolar approach and nonsubmerged healing
Study: 31044510
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant placement combined with maxillary sinus floor elevation utilizing the transalveolar approach and nonsubmerged healing
Study: 28467771
Drug: Reduction of
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduction of CTC enumeration after two cycles of chemotherapy
Study: 9972339
Drug: Topical carbonic
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical carbonic anhydrase inhibitor (dorzolamide) in association with beta-blockers
Study: 9972339
Drug: Topical carbonic
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical carbonic anhydrase inhibitor (dorzolamide) in association with beta-blockers and miotics
Study: 3134314
Drug: Nitroglycerin ointment
Normalized name: Nitroglycerin Ointment
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin ointment placed on the upper arm